PEDIATRICS Vol. 108 No. 3 September 2001, pp. 763-765
COMMENTARY:
Neonatal Jaundice and Kernicterus
OBJECTIVE
The American Academy of Pediatrics (AAP)
Subcommittee on Hyperbilirubinemia is currently revising the practice
parameter (guidelines) on neonatal hyperbilirubinemia published in
October 1994.1 Although this revision is in progress, the
Subcommittee wishes to bring the issue of kernicterus to the attention
of the pediatric community and provide additional information pending a
more formal assessment of the literature and an analysis of the risks
and benefits of new approaches to the jaundiced infant. The Joint Commission on Accreditation of Healthcare Organizations has already issued an alert on this subject.2
BACKGROUND
Kernicterus, or bilirubin encephalopathy, is a condition caused by
bilirubin toxicity to the basal ganglia and various brainstem nuclei.
In the acute phase, severely jaundiced infants become lethargic,
hypotonic and suck poorly. If the hyperbilirubinemia is not treated,
the infant becomes hypertonic and may develop a fever and a
high-pitched cry. The hypertonia is manifested by backward arching of
the neck (retrocollis) and trunk (opisthotonus). Surviving infants
usually develop a severe form of athetoid cerebral palsy, hearing loss,
dental dysplasia, paralysis of upward gaze and, less often,
intellectual and other handicaps.
Kernicterus is a condition that is unfamiliar to most pediatricians
practicing today. In the 1940s and 1950s, kernicterus was a common
complication of hyperbilirubinemia associated with Rh erythroblastosis
fetalis and, occasionally, ABO hemolytic disease. With the introduction
of exchange transfusion, kernicterus became much less common. The use
of Rh immunoglobulin all but eliminated erythroblastosis fetalis and
phototherapy drastically reduced the need for exchange transfusion. In
the last several years, however, there have been reports of kernicterus
associated with extremely high serum bilirubin levels.3-9 Most of these infants did not have obvious hemolytic disease or another
recognized cause of neonatal jaundice. Many appeared to be otherwise
healthy, breastfeeding newborns although frequently they were not
receiving adequate nutrition and hydration. A significant proportion
were <38 weeks' gestation (near-term infants).7
RISK FACTORS FOR SEVERE HYPERBILIRUBINEMIA
A comprehensive list of risk factors for severe hyperbilirubinemia
can be found in a recent review.10 The common clinical
risk factors identified in epidemiologic
studies11 are listed in Table
1 in approximate order of importance. Additional risk factors can be identified by laboratory or bedside measurement.12,13 They include Rh and ABO incompatibility,
glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and an elevated
hour-specific serum or transcutaneous bilirubin level.12,13 Rh disease is now rare and the blood type and
Rh sensitization status of the mother is usually known at the time of a
delivery, but many hospitals are no longer performing routine blood
typing in infants of group O mothers so that the ABO status of the
infant is often unknown. G-6-PD deficiency occurs in 11% to 13% of
blacks14 and is more common among immigrants from the
Mediterranean countries and Southeast Asia. It has been associated with
cases of kernicterus in the United States.3,6,7 However,
screening for G-6-PD deficiency is not performed routinely, in most
hospitals the turnaround time for laboratory testing is 2 to 3 days,
and appropriate evaluation for infants with abnormal levels is not well-defined.
TABLE 1
Common Clinical Risk Factors for Severe
Hyperbilirubinemia*
ROOT CAUSES OF IDENTIFIED CASES OF KERNICTERUS
Individual members of the committee have undertaken detailed review of published and unpublished cases of kernicterus; these reviews have used the framework of root cause analysis to identify likely fundamental underlying contributors to these cases.15 This analysis has identified the following potentially correctable causes for kernicterus:
- Early discharge (<48 hours) with no early follow-up (within 48 hours of discharge). This problem is particularly important in near-term infants (35-37 weeks' gestation).
- Failure to check the bilirubin level in an infant noted to be jaundiced in the first 24 hours.
- Failure to recognize the presence of risk factors for hyperbilirubinemia.
- Underestimating the severity of jaundice by clinical (ie, visual) assessment.
- Lack of concern regarding the presence of jaundice.
- Delay in measuring serum bilirubin level despite marked jaundice or in initiating phototherapy in the presence of elevated bilirubin levels.
- Failure to respond to parental concern regarding jaundice, poor feeding, or lethargy.
CHANGES IN NEWBORN CARE
Over the past decade, the most striking change in newborn practice has been the shortening of hospital stays.16 Shortened length of stay can affect the risk of severe jaundice in 2 ways. First, discharge at 48 hours or less means that in breastfeeding mothers the milk has not yet come in. These infants are therefore at risk for receiving inadequate fluid and nutrition, particularly if they are <38 weeks' gestation. Inadequate intake and hepatic immaturity together also place these infants at much greater risk for developing hyperbilirubinemia.11 In addition, short hospital stays mean that in almost all infants the peak bilirubin level will not occur until after discharge. Taken together, these changes mean that the management of neonatal jaundice is primarily an outpatient problem and that particular attention must be paid to breastfeeding infants and to infants who are <38 weeks' gestation.
CURRENT AAP GUIDELINES
The current AAP practice guidelines outline an approach to the management of the jaundiced newborn.1 All pediatricians should be familiar with the existing guidelines of the AAP, also available on the AAP's Web site at www.aap.org/policy/hyperb.htm. Although these guidelines cannot be applied to all cases, clinicians should document their management strategies including any significant deviation from the guidelines and the rationale for the course of action taken.
The current guidelines address only healthy infants
37 weeks'
gestation who do not have hemolytic disease. Preterm and sick infants
and infants with hemolysis require much closer follow-up and more
aggressive therapy. In otherwise healthy full-term and near-term
newborn infants, kernicterus occurs only in the presence of severe
hyperbilirubinemia. Thus, appropriate surveillance of newborns should
identify those in need of phototherapy and, if necessary, exchange
transfusion. If the current AAP guidelines for surveillance and
treatment are followed, most cases of kernicterus should be prevented.
This surveillance requires assessment in the nursery, early follow-up,
and outpatient monitoring.
RECOMMENDATIONS
Current AAP Guidelines
Recommendations from the current guidelines that deserve emphasis include the following:
- Any infant who is jaundiced before 24 hours requires a measurement of the serum bilirubin level and, if it is elevated,12 the infant should be evaluated for possible hemolytic disease.1
- Follow-up should be provided within 2 to 3 days of discharge to all neonates discharged at <48 hours after birth. Early follow-up is particularly important for infants <38 weeks' gestation. The timing of follow-up depends on the age of discharge and the presence of risk factors.11 In some cases, follow-up within 24 hours is necessary.
Risk Assessment
If early follow-up as currently recommended is uncertain or impossible, a decision regarding the timing of discharge or other follow-up should be based on risk assessment. There are now well-documented clinical and laboratory strategies for identifying newborns at risk for developing severe hyperbilirubinemia.11,12,13,16 They include the use of common clinical risk factors (Table 1) and the calculation of a risk index for predicting hyperbilirubinemia.11 An alternative strategy involves measurement of a serum or transcutaneous bilirubin level before discharge,12,13,16 which places an infant in a low, intermediate, or high-risk category for the subsequent development of hyperbilirubinemia. The timing of follow-up and the need for additional bilirubin levels will depend on the infant's age and the assessed risk.
Breastfeeding Support
Active support and advice to breastfeeding mothers should be provided both in the hospital and after discharge to ensure adequacy of intake for breastfed newborns.
Information for Parents
Pediatricians should convey a balanced approach when communicating with parents about jaundice. Most infants will become jaundiced and in the overwhelming majority of these infants, jaundice is entirely benign. A small fraction of these infants is at risk for developing extreme hyperbilirubinemia and kernicterus. As with other conditions in pediatrics (such as fever in the young infant), monitoring and surveillance of many infants are necessary to prevent a few infants from coming to harm. As with febrile infants, risk assessment strategies are needed to reliably identify almost all infants who are at serious risk of harm, while minimizing the burden and potential labeling of infants who are well.
AREAS REQUIRING ADDITIONAL RESEARCH
Incidence of Kernicterus and Outcomes
Neonatal jaundice is very common but kernicterus is rare. Thus it is regrettable that no data exist on the incidence and prevalence of kernicterus in the US population. Such data are necessary to quantify the risks, benefits, and costs of various strategies aimed at preventing kernicterus.
Additional research is also needed on the relationship of known risk factors to the development of kernicterus as well as more subtle developmental sequelae that have been associated with hyperbilirubinemia. These risk factors include the serum bilirubin level, duration of hyperbilirubinemia, the binding of bilirubin to albumin, gestational age, hemolysis, sepsis, acidosis, and other factors affecting the entry of bilirubin into the brain as well as the susceptibility of the neurons themselves to bilirubin toxicity.10 Evaluation of the effect of treatment on these risk factors and outcomes is also needed.
Predicting Hyperbilirubinemia
Measurement of a serum or transcutaneous bilirubin level on every infant before discharge has been recommended as a standard screening procedure to identify the level of risk for severe hyperbilirubinemia and the need for follow-up bilirubin levels.12,13 Measurement of end-tidal carbon monoxide levels, an index of bilirubin production, can provide information about the presence or absence of hemolysis.17 Additional research is needed to quantify the risks, benefits, and costs of these and other strategies to prevent kernicterus. Until such information is available, the 1994 practice guidelines represent a good approach for most infants.
CONCLUSION
Recent reports of kernicterus indicate that this condition, although rare, is still occurring, yet most cases are preventable. This commentary emphasizes the importance of universal and close follow-up, responsiveness to parental concerns, and awareness of the real risk of extreme hyperbilirubinemia and kernicterus. In addition, particular attention should be paid to breastfeeding infants and to near-term infants who are at significant risk for severe hyperbilirubinemia.
AAP Subcommittee on Neonatal Hyperbilirubinemia
M. Jeffrey Maisels, MB, BCh, Chairperson
Richard D. Baltz, MD
Vinod K. Bhutani, MD
Thomas B. Newman, MD, MPH
Warren Rosenfeld, MD
David K. Stevenson, MD
Howard B. Weinblatt, MD
Consultant
Charles J. Homer, MD, MPH
Chairperson, AAP
Committee on Quality Improvement
Staff
Carla Herrerias
From the American Academy of Pediatrics, Subcommittee on
Neonatal Hyperbilirubinemia.
FOOTNOTES
Received for publication Jun 5, 2001; accepted Jun 5, 2001.
Reprint requests to (M.J.M.) Department of Pediatrics, William Beaumont Hospital, 3601 W Thirteen Mile Rd, Royal Oak, MI 48073-6769. E-mail: jmaisels{at}beaumont.edu
ABBREVIATIONS
AAP, American Academy of Pediatrics; G-6-PD, glucose-6-phosphate dehydrogenase.
REFERENCES
-
American Academy of Pediatrics, Provisional Committee for Quality
Improvement and Subcommittee on Hyperbilirubinemia
Practice parameter:
management of hyperbilirubinemia in the healthy term newborn.
Pediatrics
1994;
94:558-562
[Abstract/Free Full Text] - Joint Commission on Accreditation of Healthcare Organizations. Sentinel Event Alert. Oak Brook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 2001
-
Penn AA,
Enzmann DR,
Hahn JS,
Stevenson DK
Kernicterus in a full term
infant.
Pediatrics
1994;
93:1003-1006
[Abstract/Free Full Text] -
MacDonald M
Hidden risks: early discharge and bilirubin toxicity due
to glucose-6-phosphate dehydrogenase deficiency.
Pediatrics
1995;
96:734-738
[Abstract/Free Full Text] -
Maisels MJ,
Newman TB
Kernicterus in otherwise healthy, breast-fed
term newborns.
Pediatrics
1995;
96:730-733
[Abstract/Free Full Text] - Washington EC, Ector W, Abboud M, Hemolytic jaundice due to G6PD deficiency causing kernicterus in a female newborn. South Med J 1995; 88:776-779 [Medline]
- Johnson L, Brown AK A pilot registry for acute and chronic kernicterus in term and near-term infants. Pediatrics. 1999; 104:736
- Ebbesen F Recurrence of kernicterus in term and near-term infants in Denmark. Acta Paediatr 2000; 89:1-5 [Medline]
-
Harris MC,
Bernbaum JC,
Polin JR,
Zimmerman R,
Polin RA
Developmental
follow-up of breast-fed term and near-term infants with marked
hyperbilirubinemia.
Pediatrics
2001;
107:1075-1080
[Abstract/Free Full Text] -
Dennery PA,
Seidman DS,
Stevenson DK
Neonatal
hyperbilirubinemia
. N Engl J Med
2001;
344:581-590
[Free Full Text] -
Newman TB,
Prediction and prevention of extreme
hyperbilirubinemia in a mature health maintenance organization.
Arch Pediatr Adolesc Med
2000;
154:1140-1147
[Abstract/Free Full Text] -
Bhutani VK,
Johnson L,
Sivieri EM
Predictive ability of a predischarge
hour-specific serum bilirubin for subsequent significant bilirubinemia
in healthy term and near-term newborns.
Pediatrics
1999;
103:6-14
[Abstract/Free Full Text] - Bhutani VK, Crossley GR, Adler S, et al. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn to assess the risk of severe hyperbilirubinemia. Pediatrics. 2000;106(2). Available at: http://www.pediatrics.org/cgi/content/full/106/2/e17
-
Kaplan M,
Hammerman C
Glucose-6-phosphate dehydrogenase-deficient
neonates. A potential cause for concern in North America.
Pediatrics
2000;
106:1478-1480
[Free Full Text] - Joint Commission on Accreditation of Healthcare Organizations. Sentinel Event Policy and Procedures. Oak Brook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; Available at: www.jcaho.org
-
Eaton AP
Early postpartum discharge: recommendations from a
preliminary report to Congress.
Pediatrics
2001;
107:400-404
[Free Full Text] -
Stevenson DK,
Fanaroff AA,
Maisels MJ,
Prediction of
hyperbilirubinemia in near-term and term infants.
Pediatrics.
2001;
108:31-39
[Abstract/Free Full Text]
Pediatrics (ISSN 0031 4005). Copyright ©2001 by the American Academy of Pediatrics
This article has been cited by other articles:
![]() |
A. Okumura, H. Kidokoro, H. Shoji, T. Nakazawa, M. Mimaki, K. Fujii, H. Oba, and T. Shimizu Kernicterus in Preterm Infants Pediatrics, June 1, 2009; 123(6): e1052 - e1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Maisels and A. F. McDonagh Phototherapy for Neonatal Jaundice N. Engl. J. Med., February 28, 2008; 358(9): 920 - 928. [Full Text] [PDF] |
||||
![]() |
N. Muslu, A. B. Turhan, G. Eskandari, A. Atici, O. G. Ozturk, S. Kul, and U. Atik The Frequency of UDP-Glucuronosyltransferase 1A1 Promoter Region (TA)7 Polymorphism in Newborns and it's Relation with Jaundice J Trop Pediatr, February 1, 2007; 53(1): 64 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Datar and N. Sood Impact of Postpartum Hospital-Stay Legislation on Newborn Length of Stay, Readmission, and Mortality in California Pediatrics, July 1, 2006; 118(1): 63 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-X. Chen, V. C. N. Wong, and K.-Y. Wong Neurodevelopmental Outcome of Severe Neonatal Hemolytic Hyperbilirubinemia J Child Neurol, June 1, 2006; 21(6): 474 - 479. [Abstract] [PDF] |
||||
![]() |
W.-X. Chen and V. Wong Visual Evoked Potentials in Neonatal Hyperbilirubinemia J Child Neurol, January 1, 2006; 21(1): 58 - 62. [Abstract] [PDF] |
||||
![]() |
M Kaplan and C Hammerman American Academy of Pediatrics guidelines for detecting neonatal hyperbilirubinaemia and preventing kernicterus Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2005; 90(6): F448 - F449. [Full Text] [PDF] |
||||
![]() |
G. R. Gourley, Z. Li, B. L. Kreamer, and M. R. Kosorok A Controlled, Randomized, Double-Blind Trial of Prophylaxis Against Jaundice Among Breastfed Newborns Pediatrics, August 1, 2005; 116(2): 385 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Watchko Vigintiphobia Revisited Pediatrics, June 1, 2005; 115(6): 1747 - 1753. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Kaplan, M Muraca, H J Vreman, C Hammerman, M T Vilei, F F Rubaltelli, and D K Stevenson Neonatal bilirubin production-conjugation imbalance: effect of glucose-6-phosphate dehydrogenase deficiency and borderline prematurity Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2005; 90(2): F123 - F127. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Newman, P. Liljestrand, and G. J. Escobar Combining Clinical Risk Factors With Serum Bilirubin Levels to Predict Hyperbilirubinemia in Newborns Arch Pediatr Adolesc Med, February 1, 2005; 159(2): 113 - 119. [Abstract] [Full Text] [PDF] |
||||
![]() |
Committee on Fetus and Newborn Levels of Neonatal Care Pediatrics, November 1, 2004; 114(5): 1341 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Suresh and R. E. Clark Cost-Effectiveness of Strategies That Are Intended to Prevent Kernicterus in Newborn Infants Pediatrics, October 1, 2004; 114(4): 917 - 924. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Maisels and on behalf of the Subcommittee on Hyperbilirubinemi Hyperbilirubinemia Guidelines and Unintended Harms: In Reply Pediatrics, October 1, 2004; 114(4): 1135 - 1137. [Full Text] [PDF] |
||||
![]() |
R. H. Palmer, S. Ezhuthachan, C. Newman, M. J. Maisels, and M. A. Testa Hyperbilirubinemia Benchmarking Pediatrics, September 1, 2004; 114(3): 902 - 904. [Full Text] [PDF] |
||||
![]() |
M. J. Maisels, E. M. Ostrea Jr, S. Touch, S. E. Clune, E. Cepeda, E. Kring, K. Gracey, C. Jackson, D. Talbot, and R. Huang Evaluation of a New Transcutaneous Bilirubinometer Pediatrics, June 1, 2004; 113(6): 1628 - 1635. [Abstract] [Full Text] [PDF] |
||||
![]() |
Committee on Fetus and Newborn Hospital Stay for Healthy Term Newborns Pediatrics, May 1, 2004; 113(5): 1434 - 1436. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. U. Sarici, M. A. Serdar, A. Korkmaz, G. Erdem, O. Oran, G. Tekinalp, M. Yurdakok, and S. Yigit Incidence, Course, and Prediction of Hyperbilirubinemia in Near-Term and Term Newborns Pediatrics, April 1, 2004; 113(4): 775 - 780. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. K. Bhutani and L. H. Johnson Urgent Clinical Need for Accurate and Precise Bilirubin Measurements in the United States to Prevent Kernicterus Clin. Chem., March 1, 2004; 50(3): 477 - 480. [Full Text] [PDF] |
||||
![]() |
S.-C. Chou, R. H. Palmer, S. Ezhuthachan, C. Newman, B. Pradell-Boyd, M. J. Maisels, and M. A. Testa Management of Hyperbilirubinemia in Newborns: Measuring Performance by Using a Benchmarking Model Pediatrics, December 1, 2003; 112(6): 1264 - 1273. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Javier, A. Krauss, and M. Nesin Corrected End-Tidal Carbon Monoxide Closely Correlates With the Corrected Reticulocyte Count in Coombs' Test-Positive Term Neonates Pediatrics, December 1, 2003; 112(6): 1333 - 1337. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Palmer, M. Clanton, S. Ezhuthachan, C. Newman, J. Maisels, P. Plsek, and S. Salem-Schatz Applying the "10 Simple Rules" of the Institute of Medicine to Management of Hyperbilirubinemia in Newborns Pediatrics, December 1, 2003; 112(6): 1388 - 1393. [Full Text] [PDF] |
||||
![]() |
T. B. Newman, P. Liljestrand, and G. J. Escobar Infants With Bilirubin Levels of 30 mg/dL or More in a Large Managed Care Organization Pediatrics, June 1, 2003; 111(6): 1303 - 1311. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Huang, J. Zhang, S. S. Chua, M. Qatanani, Y. Han, R. Granata, and D. D. Moore Induction of bilirubin clearance by the constitutive androstane receptor (CAR) PNAS, April 1, 2003; 100(7): 4156 - 4161. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kaplan, C. Hammerman, and M. J. Maisels Bilirubin Genetics for the Nongeneticist: Hereditary Defects of Neonatal Bilirubin Conjugation Pediatrics, April 1, 2003; 111(4): 886 - 893. [Full Text] [PDF] |
||||
![]() |
V. K. Bhutani and L. H. Johnson Kernicterus: Lessons for the Future From a Current Tragedy NeoReviews, February 1, 2003; 4(2): e30 - 32. [Full Text] [PDF] |
||||
![]() |
T. B. Newman, P. Liljestrand, and G. J. Escobar Jaundice Noted in the First 24 Hours After Birth in a Managed Care Organization Arch Pediatr Adolesc Med, December 1, 2002; 156(12): 1244 - 1250. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||













